ReviewJournal of scleroderma and related disorders2021
COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic.
Review in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- 56-year trends and disparities in systemic sclerosis mortality in the United States, 1968-2023: a retrospective population-based study.Rheumatology advances in practice · 2026Article
- Mendelian randomization unveils genetic causal relationships between viral infections and systemic sclerosis.Scientific reports · 2025Article
- [COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- IgA vasculitis after COVID-19: a case-based review.Rheumatology international · 2024Review
- A Sjögren's syndrome patient rapidly progressed to scleroderma renal crisis after COVID-19 infection.Rheumatology advances in practice · 2024Article
- Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients.Turkish journal of medical sciences · 2024Article
- SARS-CoV-2 spike protein accelerates systemic sclerosis by increasing inflammatory cytokines, Th17 cells, and fibrosis.Journal of inflammation (London, England) · 2023Article
- COVID-19 and protection of vaccination in patients with systemic sclerosis-associated interstitial lung disease.Journal of scleroderma and related disorders · 2023Article
- Systemic sclerosis.Lancet (London, England) · 2023Review
- Systemic sclerosis in the time of COVID-19.The Lancet. Rheumatology · 2022Review
- Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination.Journal of autoimmunity · 2022Review
- Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis.Journal of clinical medicine · 2022Article
- The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.Journal of multidisciplinary healthcare · 2022Review
- Scleroderma renal crisis following Covid-19 infection.Journal of scleroderma and related disorders · 2021Article
- Sodium Toxicity in the Nutritional Epidemiology and Nutritional Immunology of COVID-19.Medicina (Kaunas, Lithuania) · 2021Article
- Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe.Journal of scleroderma and related disorders · 2021Article
- Cardiopulmonary predictors of mortality in patients with COVID-19: What are the findings?Archives of cardiovascular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19, caused by infection of the novel coronavirus SARS-CoV-2, has caused a pandemic of enormous impact that has challenged healthcare and political system throughout the world. This new health emergency has occurred on top of the usual burden of diseases, including systemic sclerosis, and has led to many unanticipated consequences. An early consequence of the pandemic was postponement of the Sixth Systemic Sclerosis World Congress that was recently completed as a successful virtual congress with more than 1000 delegates. In this article, we summarise the relevance and impact of COVID-19 from the perspective of systemic sclerosis. Shared concepts of pathogenesis are considered, and the relevant literature emerging about COVID-19 and systemic sclerosis summarised. The specific impact of this pandemic on delivery of optimal scleroderma care is considered, together with the broader effect on rheumatic and musculoskeletal diseases and the activities of European League Against Rheumatism. As the World continues to struggle against this new infectious disease, it is notable that expertise and growing understanding of systemic sclerosis has been able to help tackle COVID-19. Moreover, the essential adjustments to deliver clinical care and establishment of new ways of working due to the pandemic have offered potential avenues for future improvement in systemic sclerosis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.